| 0.8657 -0.008 (-0.88%) | 01-27 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.23 | 1-year : | 1.44 |
| Resists | First : | 1.05 | Second : | 1.23 |
| Pivot price | 0.77  |
|||
| Supports | First : | 0.77 | Second : | 0.6 |
| MAs | MA(5) : | 0.86 | MA(20) : | 0.77 |
| MA(100) : | 1.03 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.4 | D(3) : | 71.4 |
| RSI | RSI(14): 54.2 | |||
| 52-week | High : | 3.73 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZIOP ] has closed below upper band by 22.6%. Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
Thu, 25 Apr 2024
Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update - The Globe and Mail
Thu, 25 Apr 2024
WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - The Globe and Mail
Thu, 25 Apr 2024
Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to ... - The Globe and Mail
Thu, 25 Apr 2024
Ziopharm Oncology to Participate in September Investor Conferences - The Globe and Mail
Thu, 25 Apr 2024
Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates - The Globe and Mail
Thu, 25 Apr 2024
Discovery Capital Management Will Vote For All of WaterMill’s Stated Proposals at Ziopharm Oncology - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 216 (M) |
| Held by Insiders | 1.7244e+008 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 32,730 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.566e+007 |
| EPS Est Next Qtrly | -0.15 |
| EPS Est This Year | -0.57 |
| EPS Est Next Year | -0.61 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -22 % |
| Return on Assets (ttm) | 103.5 % |
| Return on Equity (ttm) | -39.4 % |
| Qtrly Rev. Growth | 398000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -48.01 |
| EBITDA (p.s.) | -3.01143e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 4.73 |
| Dividend | 0 |
| Forward Dividend | 3.452e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|